

CMP:	Rs. 4,401
Target Price:	Rs. 4,975
Recommendation:	ACCUMULATE

Stock Info		
BSE Group	А	
BSE Code	500674	
NSE Symbol	SANOFI	
Bloomberg	SANL IN	
Reuters	SANO.BO	
BSE Sensex	25,606	
NSE Nifty	7,850	

Market Info		
Market Capital	10,134 Cr	
Equity Capital	23 Cr	
Avg. Trading Vol.	13,480 Cr	
52 Wk High/ Low	4,651/3,090	
Face Value	Rs 10	

Shareholding Pattern (%)	(Dec 2015)
Promoters	60.4
Domestic Institutions	26.4
Foreign Institutions	2.7
Public & Others	10.5

Price Chart:



Whopping Improvement in EBITDA margin!

2nd May, 2016

Sanofi India reports 66.5% rise in Q1 net profit

Sanofi India has reported better than expected numbers for first quarter ended March 31, 2016. The company has posted a rise of 66.5 per cent in its net profit at Rs 81 crore for the quarter ended March 31, 2016 as compared to Rs 48 crore for the same quarter in the previous year. Net profit including the effect of exceptional items of Rs 16.1 crore reported in corresponding quarter of last year increased by 25%. Meanwhile, total income of the company has increased by 11.4 per cent to Rs 544 crore for quarter under review as compared to Rs 489 crore for the quarter ended March 31, 2015.

Exceptional item

Company had reported an exceptional item net of tax at Rs 16.1 crore in corresponding quarter of previous year, arising from the sale of a floor at commercial premises in Mumbai in January 2015. This quarter however no such exceptional income has been reported.

Overall expenses surges 2.3%

Overall expenses stood at Rs 415 crore for the quarter under review, an increase of 2.3 per cent as against Rs 406 crore in the corresponding period of the previous year. Cost of raw materials as a percentage of sales increased by 140 bps to 30.4% YoY. Moreover, depreciation and amortization expenses also increased Rs 30.1 crore from Rs 25.9 crore in March quarter of 2015.

Employee benefit expenses as a percentage of sales dropped down from 16.1 per cent to 15.4 per cent YoY. Operating & manufacturing expenses as a percentage of sales too plunged from 17.9% to 16.3% YoY resulting in growth of EBITDA which came in at Rs. 129 crore vs. Rs 83 crore in the corresponding quarter of previous year. EBITDA margin grew by 6.8% from 17% to 23.8% YoY.

We have valued the stock at 15 (x) EV/EBITDA & arrived at a fair value of 4,975 per share. We have **ACCUMULATE** rating on the stock.

Financial Snapshot:					
Particulars	2013	2014	2015	2016E	2017E
Income from Operations	1809	1977	2193	2463	2833
EBITDA	398	339	460	571	696
EBITDA%	22.0	17.1	21.0	23.2	24.6
Profit After Tax	265	264	322	382	475
EPS	115	114	140	166	206
ROE	20.8	18.6	20.7	22.2	24.2
P/E (x)	23.9	31.4	31.3	26.5	21.3
EV/EBITDA (x)	15.2	23.0	20.7	16.5	13.1

Financial Snapshot



Arihant Research Desk

E. research@arihantcapital.com T. 022-42254800

Head Office	Registered Office
 #1011, Solitaire Corporate park, Building No. 10, 1st Floor, Andheri Ghatkopar Link Road, Chakala, Andheri (E). Mumbai - 400093 Tel: (91-22) 42254800 Fax: (91-22) 42254880 	E-5 Ratlam Kothi Indore - 452003, (M.P.) Tel: (91-731) 3016100 Fax: (91-731) 3016199

Stock Rating Scale

	Absolute Return
Buy	> 20%
Accumulate	12% to 20%
Hold	5% to 12%
Neutral	-5% to 5%
Reduce	< -5%

Research Analyst Registration No.	Contact	Website	Email Id
INH000002764	SMS: 'Arihant' to 56677	www.arihantcapital.com	research@arihantcapital.com

Disclaimer:

This document has been prepared by Arihant Capital Markets Ltd. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Arihant may trade in investments, which are the subject of this document or in related investments and may have acted upon or used the information contained in this document or the research or the analysis on which it is based, before its publication. This is just a suggestion and Arihant will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Affiliates of Arihant may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. No matter contained in this document may be reproduced or copied without the consent of the firm.

ARIHANT Capital Markets Ltd. www.arihantcapital.com Sector - Pharmaceuticals